The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke
The company was directed to submit a plan of compliance by July 15, 2022
Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection
NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
With this designation, LG Chem will receive benefits such as exclusive sales rights in the US market for seven years, subsidies and tax cuts for clinical testing costs in the US, and preliminary consulting support related to development
TLANDO was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
The peptide-based vaccine induces a t cell-dependent response
Subscribe To Our Newsletter & Stay Updated
